Profile data is unavailable for this security.
About the company
QINGHAI SPRING MEDICINAL RESOURCES TECHNOLOGY CO.,LTD is a China-based company that principally engaged in the integrated development, utilization, production, sales and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company’s main products are the cordyceps sinensis series products under Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis and raw cordyceps sinensis. The Company’s subsidiary is Qinghai Spring Pharmaceutical Resource Utilization Co Ltd.
- Revenue in CNY (TTM)251.20m
- Net income in CNY-287.99m
- Incorporated1998
- Employees173.00
- LocationQinghai Spring Medicinal Resources Technology Co Ltd16F, Ningjing Business CenterXINING 810000ChinaCHN
- Phone+86 9 718816171
- Fax+86 9 718816171
- Websitehttps://www.verygrass.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu gdk Biotechnology Co Ltd | 52.65m | -113.37m | 1.88bn | 451.00 | -- | 1.43 | -- | 35.80 | -0.9188 | -0.9188 | 0.427 | 10.69 | 0.0321 | 0.4049 | 0.5195 | 116,733.70 | -6.92 | 3.30 | -8.09 | 4.84 | 51.66 | 75.56 | -215.35 | 12.58 | 2.67 | -- | 0.0433 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
| Qinghai Spring Medicinl Rsrcs Tech CoLTD | 251.20m | -287.99m | 1.93bn | 173.00 | -- | 1.69 | -- | 7.67 | -0.4915 | -0.4915 | 0.4298 | 1.94 | 0.1843 | 0.5809 | 4.25 | 1,452,016.00 | -21.01 | -11.25 | -21.83 | -11.55 | 40.40 | 23.44 | -113.97 | -129.81 | 7.06 | -0.9897 | 0.0114 | -- | 33.52 | -8.48 | 6.85 | -- | -20.83 | -- |
| Shanghai Shen Lian Biomedical Corp | 310.36m | -19.73m | 2.21bn | 380.00 | -- | 1.52 | -- | 7.13 | -0.048 | -0.048 | 0.7558 | 3.56 | 0.1944 | 1.16 | 0.9692 | 816,747.00 | -1.48 | 5.39 | -1.58 | 5.84 | 60.66 | 77.45 | -7.62 | 25.48 | 5.14 | -- | 0.0012 | 38.49 | -8.25 | 1.85 | -48.41 | -18.49 | 10.47 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 197.30m | 50.92m | 2.22bn | 321.00 | 43.59 | 1.99 | -- | 11.25 | 0.4706 | 0.4706 | 1.82 | 10.30 | 0.1735 | 1.14 | 3.91 | 614,647.90 | 4.48 | 10.43 | 4.56 | 10.84 | 76.60 | 80.54 | 25.81 | 32.57 | 42.72 | -- | 0.004 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
Data as of Sep 13 2024. Currency figures normalised to Qinghai Spring Medicinal Resources Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gfund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| HFT Investment Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
